Herantis Pharma (HEL: HRTIS)

Last close As at 26/11/2025

EUR2.17

0.05 (2.36%)

Market capitalisation

EUR52m

Arron Aatkar, PhD | Healthcare | Comment | 20 hours ago
Arron Aatkar, PhD | Healthcare | Comment | 20 hours ago

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.

Latest Insights

View More

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Healthcare | edison tv

Webinar: The CNS renaissance Biotech companies at the forefront

Healthcare | edison tv

Herantis Pharma – executive interview

Healthcare | Spotlight — flash

Herantis Pharma — HER-096 clears Phase Ib, eyes Phase II

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Antti Vuolanto

    CEO

  • Tone Kvåle

    CFO

Research

Spotlight — update

Healthcare

Herantis Pharma — H125 results reflect Phase Ib progress

Spotlight — flash

Healthcare

Herantis Pharma — Last patient visit completed for Phase Ib

Spotlight — initiation

Healthcare

Herantis Pharma — Dedicated to disease modification for PD

edison tv

Healthcare

Herantis Pharma – executive interview

Quickview

Healthcare

Herantis Pharma — Potential disease-modifier for PD